Company facts
- Headquarters
- New York, New York
- Most recent report
- 8-K, filed Nov 3, 2026
- Incorporated
- N/A
- Filings on record
- 638 filings
- On EDGAR
- CIK 1314052
- Fiscal year ends
- September
- Filer status
- Large accelerated filer, Smaller reporting company
Financials 8 of 80
News 8 of 140
Prospectuses and Registrations 8 of 41
- 424B5 Prospectus supplement for an offering Jul 25, 2025
- S-3 Shelf registration statement Jul 14, 2025
- S-3 Shelf registration statement Jul 29, 2024
- 424B5 Prospectus supplement for an offering Feb 7, 2023
- S-8 Registration statement for an employee plan Jun 10, 2022
- S-3ASR Automatic shelf registration Sep 24, 2021
- 424B5 Prospectus supplement for an offering Jun 24, 2021
- S-8 Registration statement for an employee plan Apr 9, 2021
Proxies 8 of 36
- DEFA14A Extra proxy material Sep 15, 2026
- DEFA14A Extra proxy material Sep 14, 2026
- DEFA14A Extra proxy material Sep 8, 2026
- DEFA14A Extra proxy material Sep 4, 2026
- DEFA14A Extra proxy material Sep 1, 2026
- DEFA14A Extra proxy material Aug 31, 2026
- DEFA14A Extra proxy material Aug 24, 2026
- DEFA14A Extra proxy material Aug 17, 2026
Ownership 8 of 229
- 4 Insider reported a trade Nov 6, 2026
- 4 Insider reported a trade Nov 6, 2026
- 4 Insider reported a trade Nov 6, 2026
- 4 Insider reported a trade Nov 6, 2026
- 3 Insider reported their initial holding Oct 5, 2026
- 3 Insider reported their initial holding Oct 5, 2026
- 4 Insider reported a trade Sep 28, 2026
- SCHEDULE 13G Large holder reported a passive stake Jul 31, 2026
Other 8 of 112
Everything here comes from Anavex Life Sciences Corp.'s own filings on SEC EDGAR. The filing list is rechecked every hour.